Premenstrual Dysphoric Disorder (PMDD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Premenstrual Dysphoric Disorder (PMDD) Market Outlook

Thelansis’s “Premenstrual Dysphoric Disorder (PMDD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Premenstrual Dysphoric Disorder treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Premenstrual Dysphoric Disorder (PMDD) Overview

Premenstrual Dysphoric Disorder (PMDD) is a depressive disorder categorized as "not otherwise specified" in the Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Association. It is characterized by mood, appetite, energy, and cognitive changes that manifest during the menstrual cycle's late luteal (premenstrual) phase and subside shortly after the onset of menses. The onset of symptoms is closely linked to the late luteal phase, which coincides with declining levels of estrogen and progesterone. Symptom relief typically occurs during the initial days of the follicular phase when estrogen levels increase due to ovarian follicular growth. The exact cause of PMS/PMDD remains unknown. However, certain risk factors are associated with the development of the condition, some of which have been well-established, while others are still speculative. Proven Risk Factors: 1. Past traumatic events: Traumatic experiences and preexisting anxiety disorders are identified as risk factors for PMDD. 2. Cigarette smoking: A significant link exists between moderate-to-severe forms of PMS and current smoking status, with an elevated risk for former smokers. 3. Obesity: A clear linear relationship exists between baseline Body Mass Index (BMI) and the risk of incident PMS. Each 1 kg/m2 increase in BMI is associated with a significant 3% increase in risk. Speculative Risk Factor: 1. Genetics: Heritable factors play a role in developing PMS/PMDD. The involvement of specific genes, such as the one coding for the serotonergic 5HT1A receptor and allelic variants of the estrogen receptor alpha gene (ESR1), in developing PMS/PMDD. The symptoms of PMDD may overlap with other psychiatric disorders, particularly major depression. Thus, it is crucial to rule out the presence of another existing disorder before confirming the diagnosis of PMS/PMDD. The key factor in diagnosing PMDD is the temporal association of symptoms with the menstrual cycle. Pharmacological approaches to managing PMDD include the use of psychotropic agents and hormonal therapies:

1. Psychotropic agents: Selective serotonin reuptake inhibitors (SSRIs) have been shown to treat severe mood and somatic symptoms of PMDD effectively. Antidepressants that primarily affect noradrenergic transmission are less effective for PMDD, indicating that the beneficial effects of SSRIs are not solely due to their antidepressant properties. The positive effects of SSRIs on PMDD symptoms manifest rapidly compared to their antidepressant effects.
2. Benzodiazepines (BZDs): BZDs like alprazolam can be effective in women with severe anxiety and premenstrual insomnia. However, caution is advised due to the risk of dependence, especially in cases with a history of substance abuse.
3. Suppression of Ovulation: Hormonal therapies can be considered for severe symptoms of PMDD.

Danazol: This synthetic partial androgen agonist/antagonist and gonadotropin inhibitor has demonstrated efficacy in treating PMDD by inhibiting ovulation. However, it is associated with hirsutism and teratogenicity, making it less preferred as an initial treatment. - Oral contraceptive pills (OCPs): While commonly used in clinical practice. Women on OCPs may experience hormone-related symptoms during hormone-free days, suggesting that OCPs with fewer hormones might benefit more. Drospirenone, a gestagen, has effectively treated PMDD symptoms due to its anti-aldosterone and anti-androgenic effects.

• Up to 80% of women in the United States go through emotional, behavioral, or physical premenstrual symptoms. Additionally, approximately 3% to 8% of women meet the diagnostic criteria for PMDD.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: